{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"omics_type":["Unknown"],"volume":["53"],"submitter":["Thakar A"],"pubmed_abstract":["<i>Introduction</i> During the COVID-19 pandemic in India, Ayurvedic medication (<i>Guduchi Ghanavati,</i> GG) was prescribed by Ayurveda physicians for prevention and management. This study aimed to evaluate the prophylactic effect of GG in individuals with moderate to very high risk of SARS-CoV-2. <i>Methods</i> A multicenter, controlled, quasi-experimental, before-and-after study was conducted on individuals at moderate to very high risk of SARS-COV-2 exposure. In the intervention group (<i>n</i> = 15,992), participants received GG 1 g daily for 28 days in conjunction with standard preventive guidelines (SPG), while in the control group (<i>n</i> = 4953), participants were asked to follow SPG only. Outcomes were the incidence of COVID-19, perceived immune status, quality of life, and sa"],"journal":["European journal of integrative medicine"],"pagination":["102131"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC9047434"],"repository":["biostudies-literature"],"pubmed_title":["<i>Guduchi Ghanavati</i> (Ayurveda medication) improves the perceived immunity in individuals at risk of SARS-CoV-2: A Multicentred, controlled, before-and-after study."],"pmcid":["PMC9047434"],"pubmed_authors":["Bhinde S","Jain N","Panara K","Raghavani H","Jani D","Dodia R","Vyas J","Bhatt P","Salve R","Shah H","Thakar A","Goyal M","Ruparel S","Chaudhari S","Kalsariya B","Patel F"],"additional_accession":[]},"is_claimable":false,"name":"<i>Guduchi Ghanavati</i> (Ayurveda medication) improves the perceived immunity in individuals at risk of SARS-CoV-2: A Multicentred, controlled, before-and-after study.","description":"<i>Introduction</i> During the COVID-19 pandemic in India, Ayurvedic medication (<i>Guduchi Ghanavati,</i> GG) was prescribed by Ayurveda physicians for prevention and management. This study aimed to evaluate the prophylactic effect of GG in individuals with moderate to very high risk of SARS-CoV-2. <i>Methods</i> A multicenter, controlled, quasi-experimental, before-and-after study was conducted on individuals at moderate to very high risk of SARS-COV-2 exposure. In the intervention group (<i>n</i> = 15,992), participants received GG 1 g daily for 28 days in conjunction with standard preventive guidelines (SPG), while in the control group (<i>n</i> = 4953), participants were asked to follow SPG only. Outcomes were the incidence of COVID-19, perceived immune status, quality of life, and sa","dates":{"release":"2022-01-01T00:00:00Z","publication":"2022 Aug","modification":"2026-05-30T14:32:52.871Z","creation":"2022-07-10T00:43:53.081Z"},"accession":"S-EPMC9047434","cross_references":{"pubmed":["35506012"],"doi":["10.1016/j.eujim.2022.102131"]}}